New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2014
08:07 EDTABMDAbiomed receives CE Mark for Impella RP
Abiomed announced it has received CE Marking approval in the European Union to market the Impella RP device, a new percutaneous Impella heart pump that provides temporary ventricular support for patients with right ventricular failure. The Impella RP is a percutaneous heart pump that is implanted through a single access site in the patient's leg and deployed through the venous system, across the right side of the heart without requiring a surgical procedure. The Impella RP is not currently cleared for sale or use in the United States.
News For ABMD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 4, 2016
07:07 EDTABMDAbiomed sees Q4 revenue $90M, consensus $85.11M
Subscribe for More Information
07:07 EDTABMDAbiomed raises FY16 revenue outlook to $326M from $305M-$315M
Subscribe for More Information
07:06 EDTABMDAbiomed reports Q3 EPS 23c, consensus 15c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use